Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Theragenics (TGX) on the up and up -- Ignore unavailable to you. Want to Upgrade?

To: Stephen M. DeMoss who wrote (740)	3/14/1998 2:06:00 PM
From: Stephen M. DeMoss	Read Replies (1) \| Respond to of 1055

As a side note, has anyone noticed that Thrx has double the Pe of the other companies in the industry, and double the price to book, and triple the price to sales, and triple the beta, and more than double the price to cash flow than others in the industry? The insider selling is minor to the ratios compared to the industry. Like Cabots PRST, it could fly to 200 but if the market looks at valuations, the momentum players could dump this stock and leave small investors holding the bag. I say to put in stops, just in case. Even at 58 or 55. PRST went from 200 to 20 in about 6 months. Steve D.